BioCryst Pharmaceuticals (NASDAQ:BCRX) Sets New 1-Year High – Here’s Why

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) hit a new 52-week high during trading on Thursday . The company traded as high as $10.48 and last traded at $10.6090, with a volume of 1360689 shares changing hands. The stock had previously closed at $10.00.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on BCRX shares. Wedbush dropped their price target on shares of BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a research report on Thursday, May 7th. Wall Street Zen cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Needham & Company LLC reduced their price target on shares of BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Weiss Ratings reiterated a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, June 1st. Finally, Citizens Jmp raised their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a research report on Thursday, May 7th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Stock Up 0.4%

The company has a market capitalization of $2.53 billion, a PE ratio of -5.58 and a beta of 0.57. The firm’s 50 day simple moving average is $8.90 and its 200 day simple moving average is $8.25.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing analysts’ consensus estimates of $0.06 by ($3.04). BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business had revenue of $156.41 million during the quarter, compared to analysts’ expectations of $151.12 million. During the same quarter in the previous year, the business earned $0.20 EPS. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. As a group, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC boosted its stake in BioCryst Pharmaceuticals by 1,188.0% in the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 3,267 shares in the last quarter. Focus Partners Wealth acquired a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth $77,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 2,115 shares during the last quarter. Hilltop Holdings Inc. acquired a new position in shares of BioCryst Pharmaceuticals in the 1st quarter valued at $98,000. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in BioCryst Pharmaceuticals in the 4th quarter worth $81,000. 85.88% of the stock is owned by hedge funds and other institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.